Denmark

17.03.06 Copenhagen - TopoTarget A/S and CuraGen Corp. have started treating patients in a new Phase II study of their histone deacetylase (HDAC) inhibitor, PXD101. The study will evaluate the efficacy (75 patients) and safety (25... more

Symphogen attracts investors

17.03.06 Copenhagen - Symphogen A/S, a Danish company developing recombinant human polyclonal antibodies for the treatment of several human diseases, has raised Euro20.7 million in a Series D financing round. Participators were existing... more

Aresa joined alternative market

17.03.06 Copenhagen - The Danish biotech company Aresa A/S has joined the newly formed First North Stock Exchange in February - as first biotech company and second company on the alternative marketplace in Denmark. The offering of shares... more

Effect on obesity

17.03.06 Ballerup/Ingelheim - The Danish biopharmaceutical company Neurosearch A/S has discovered by chance that one of the company's compounds, tesofensine, showed an effect on obesity during clinical studies for the treatment of... more

Survac acquired by Merck

29.01.06 Copenhagen - Darmstadt-based Merck KGaA has acquired the Danish biotechnology company Survac ApS for Euro11 million to access novel technologies for the treatment of cancer. Survac was founded three years ago in Copenhagen with... more